The research aims to explore the evolution of companion diagnostics in lung cancer treatment, particularly focusing on non-small cell lung cancer (NSCLC).
Reviewed developments in EGFR targeting since 2004.
Analyzed the role of multicdx testing in companion diagnostics.
Examined the integration of genomic medicine into lung cancer treatment strategies.
Notable advancements in companion diagnostics have improved treatment effectiveness.
EGFR mutations are now better targeted via personalized medicine.
Multicdx tests enhance the identification of suitable therapies for NSCLC.